書誌事項
- タイトル別名
-
- Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: A case study with a microemulsion formulation (Neoral).
- ―マイクロェマルジョン製剤(ネオーラル®)を使用した場合―
この論文をさがす
説明
Cyclosporin A (CyA) is used frequently in the treatment of steroid-resistant or recurrent cases with nephrotic syndrome. Recently, a new microemulsion formulation of CyA (Neoral(R)) has been developed and used preferably because of a more stable bioavailability than an oily formulation (Sandimmun(R)). Nephrotic syndrome accompanies hyperlipidemia, and probucol is used in cases showing inadequate effects or some adverse reactions under therapy with HMG-CoA reductase inhibitors. We reported previously that combined use of probucol caused a decrease in blood concentrations of CyA to about half of those without probucol. In the present study, we evaluated the influence of probucol on the blood concentrations of CyA in patients with nephrotic syndrome following Neoral(R).Coadministration of Neoral(R) and probucol decreased the blood concentrations of CyA to approximately 75 % of the levels before combined use. The change of blood CyA concentrations appeared to be smaller compared to those in cases with Sandimmun(R). Based on the present findings, we suggest that Neoral(R) should be used preferentially instead of Sandimmun(R) when the concomitant use of probucol is required, and that optimal dose adjustment of CyA is needed by frequent monitoring of CyA blood concentrations.
収録刊行物
-
- 日本腎臓学会誌
-
日本腎臓学会誌 44 (8), 792-797, 2002
社団法人 日本腎臓学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204859479040
-
- NII論文ID
- 130004170607
- 10010593968
-
- NII書誌ID
- AN10131749
-
- ISSN
- 18840728
- 03852385
-
- PubMed
- 12607968
-
- 本文言語コード
- ja
-
- 資料種別
- journal article
-
- データソース種別
-
- JaLC
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可
